HER2 and HER3 belong to the HER family of receptor tyrosine kinases and are commonly overexpressed in multiple tumor types [20–22]; their overexpression has been linked to poor clinical outcomes [23–25]. This evidence concerns the gene NTRK1 and neoplasm.